Merck/AstraZeneca lisinopril exclusivity
Executive Summary
Merck and AstraZeneca receive pediatric exclusivity through June 29 on lisinopril products (Merck's Prinivil; AstraZeneca's Zestril and Zestoretic). The companies are seeking to have the pediatric data added to labeling; FDA is reviewing supplemental NDAs. AstraZeneca licenses lisinopril from Merck...
You may also be interested in...
Pediatric Zestril
FDA approves AstraZeneca's ACE-inhibitor Zestril (lisinopril) July 1 for treatment of hypertension in children six to 16. AstraZeneca licenses the compound from Merck. The two companies had pediatric exclusivity for lisinopril products through June 29, 2002 (1"The Pink Sheet" Dec. 3, 2001, In Brief)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.